Like other molecular targeted therapies, EGFR-TKIs have the potential to improve clinical outcomes for large numbers of NSCLC patients in Asia and other regions where the prevalence of actionable molecular alterations is high (4, 5). Here, EGFR is linked to non-small cell lung carcinoma.